GENEDRIVE ORD 1.5P overview

Genedrive CEO Dr. Gino Miele talked about the company's progress in rapid pharmacogenetic testing for emergency care at the ......

RiverFort is pleased to announce that it has arranged an Equity Prepayment Facility for up to £5 million (the "Facility") with Genedrive plc (LSE: GDR) (“Genedrive” or the “Company”), the point of care molecular diagnostics company, with an initial drawn amount of £2 million and committed capital advances of up to £3 million in 10 monthly instalments of £300,000 from 30 May 2023 which may be drawn down by the Company at its election. The Facility and the Company's existing cash...

Hardman & Co Research Hardman & Co Research: genedrive plc (GDR): Western market progress but developing markets difficult 05-Feb-2020 / 07:15 GMT/BST Hardman & Co Res earch : Western market progress but developing markets difficult Genedrive plc (GDR) is a commercial-stage biotech focused on point-of-care molecular diagnostics. Its Genedrive (R) molecular diagnostic platform offers low-cost, simple-to-use devices for highly sensitive and specific testing. The rapid analysis of samples aids...

Hardman & Co Research Hardman & Co Research: genedrive plc (GDR): Regulatory hurdle leaped: hearing loss assay 21-Nov-2019 / 12:30 GMT/BST Hardman & Co Res earch : Regulatory hurdle leaped: hearing loss assay genedrive plc (GDR) is a commercial-stage company focused on point-of-care molecular diagnostics. Its Genedrive (R) molecular diagnostic platform is at the forefront of this technology, offering a rapid, low-cost, simple-to-use device with high sensitivity and specificity. Rapid analysis of...

Hardman & Co Research Hardman & Co Research: genedrive plc (GDR): Acceleration of news flow expected 28-Oct-2019 / 07:30 GMT/BST Hardman & Co Res earch : Acceleration of news flow expected genedrive plc (GDR) is a commercial-stage company focused on point-of-care molecular diagnostics. Its Genedrive (R) molecular diagnostic platform is at the forefront of this technology, offering a rapid, low-cost, simple-to-use device with high sensitivity and specificity. Rapid analysis of samples aids...

Hardman & Co Research Hardman & Co Research: genedrive plc (GDR): Hepatitis C market frustrations 18-Jul-2019 / 07:30 GMT/BST Hardman & Co Research: Hepatitis C market frustrations genedrive plc (GDR) is a commercial-stage company focused on point-of-care molecular diagnostics. Its Genedrive(R) molecular diagnostic platform is at the forefront of this technology, offering a rapid, low-cost, simple-to-use device with high sensitivity and specificity in the diagnosis of infectious diseases. Rapid...

Hardman & Co Research Hardman & Co Research: genedrive plc (GDR): First commercial sales in new focus area: bio-threats 08-Apr-2019 / 10:53 GMT/BST Hardman & Co Research: First commercial sales in new focus area: bio-threats genedrive plc (GDR) is a commercial-stage company focused on point-of-care (PoC) molecular diagnostics. Its Genedrive(R) molecular diagnostic platform is at the forefront of this technology, offering a rapid, low-cost, simple-to-use device with high sensitivity and...

Hardman & Co Research Hardman & Co Research: genedrive plc (GDR): Accelerating into fiscal 2019 with first sales 11-Dec-2018 / 07:15 GMT/BST Hardman & Co: Accelerating into fiscal 2019 with first sales genedrive plc (GDR) is a commercial-stage company focused on point-of-care molecular diagnostics. Its Genedrive(R) molecular diagnostic testing platform is at the forefront of this technology, offering a rapid, low-cost, simple-to-use device with high sensitivity and specificity in the diagnosis...